IVRA
Growthmelphalan hcl
NDAINTRAVENOUSSOLUTION
Approved
Aug 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
2
Mechanism of Action
type. As a result, its cytotoxicity appears to be related to the extent of its interstrand cross-linking with DNA, probably by binding at the N position of guanine. Like other bifunctional alkylating agents, it is active against both resting and rapidly dividing tumor cells.
Clinical Trials (2)
Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation
Started Jul 2020
PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation
Started Jan 2010
Loss of Exclusivity
LOE Date
Jun 29, 2036
125 months away
Patent Expiry
Jun 29, 2036
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 10537520 | Jun 29, 2036 | Product | — |